Seattle Genetics (SGEN) is the latest company to test the market for high-priced new drugs announcing plans Monday to charge six figures for the just-approved treatment Adcetris for two types of blood cancer.Seattle Genetics said the drug will cost between $94 500 and $121 500 per patient depending on the number of doses. The price could run even higher because it’s unknown how many doses each patient will require. (The company estimated the price based on seven to nine infusions per patient.) The pricing announcement follows Friday’s news that Adcetris received a fast US Food and Drug Administration approval ...